Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

References

• Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13(8):473–486.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. doi:https://doi.org/10.1056/NEJMra1703481.
   PubMed Web of Science ®Google Scholar
• Mizuno K, Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, et al. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. J Gastroenterol. 2020;55(6):653–661. doi:https://doi.org/10.1007/s00535-020-01677-9.
   PubMed Web of Science ®Google Scholar
• Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13(22 Pt 1):6681–6688. doi:https://doi.org/10.1158/1078-0432.CCR-07-0187.
   PubMed Web of Science ®Google Scholar
• Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, et al. Early immune-related adverse events and association with outcome in advanced non–small cell lung cancer patients treated with nivolumab: a prospective cohort study. J Thorac Oncol. 2017;12(12):1798–1805. doi:https://doi.org/10.1016/j.jtho.2017.08.022.
   PubMed Web of Science ®Google Scholar
• Judd J, Zibelman M, Handorf E, O'Neill J, Ramamurthy C, Bentota S, et al. Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors. Oncologist. 2017;22(10):1232–1237. doi:https://doi.org/10.1634/theoncologist.2017-0133.
   PubMed Web of Science ®Google Scholar
• Toi Y, Sugawara S, Kawashima Y, Aiba T, Kawana S, Saito R, et al. Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab. Oncologist. 2018;23(11):1358–1365. doi:https://doi.org/10.1634/theoncologist.2017-0384.
   PubMed Web of Science ®Google Scholar
• Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4(3):374–378. doi:https://doi.org/10.1001/jamaoncol.2017.2925.
   PubMed Web of Science ®Google Scholar
• Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer. 2018;115:71–74. doi:https://doi.org/10.1016/j.lungcan.2017.11.019.
   PubMed Web of Science ®Google Scholar
• Okada N, Kawazoe H, Takechi K, Matsudate Y, Utsunomiya R, Zamami Y, et al. Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with nivolumab: a multicenter retrospective study. Clin Ther. 2019;41(1):59–67. doi:https://doi.org/10.1016/j.clinthera.2018.11.004.
   PubMed Web of Science ®Google Scholar
• Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol. 2019;145(2):479–485. doi:https://doi.org/10.1007/s00432-018-2805-3.
   PubMed Web of Science ®Google Scholar
• Grangeon M, Tomasini P, Chaleat S, Jeanson A, Souquet-Bressand M, Khobta N, et al. Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non–small-cell lung cancer. Clin Lung Cancer. 2019;20(3):201–207. doi:https://doi.org/10.1016/j.cllc.2018.10.002.
   PubMed Web of Science ®Google Scholar
• Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, Del Vecchio M. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol. 2019;145(2):511–521. doi:https://doi.org/10.1007/s00432-018-2819-x.
   PubMed Web of Science ®Google Scholar
• Komiya K, Nakamura T, Abe T, Ogusu S, Nakashima C, Takahashi K, et al. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. Thorac Cancer. 2019;10(9):1798–1804.
   PubMed Web of Science ®Google Scholar
• Matsuoka H, Hayashi T, Takigami K, Imaizumi K, Shiroki R, Ohmiya N, et al. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody. BMC Cancer. 2020;20(1):656. doi:https://doi.org/10.1186/s12885-020-07142-3.
   Google Scholar
• Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151(11):1206–1212. doi:https://doi.org/10.1001/jamadermatol.2015.1916.
   PubMed Web of Science ®Google Scholar
• Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French LE, et al. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. Oncoimmunology. 2016;5(11):e1231292. doi:https://doi.org/10.1080/2162402X.2016.1231292.
   PubMed Web of Science ®Google Scholar
• Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22(4):886–894.
   PubMed Web of Science ®Google Scholar
• Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45–51. doi:https://doi.org/10.1001/jamadermatol.2015.2707.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Tanaka R, Asami Y, Teramoto Y, Imamura T, Sato S, et al. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study. J Dermatol. 2017;44(2):117–122. doi:https://doi.org/10.1111/1346-8138.13520.
   PubMed Web of Science ®Google Scholar
• Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim YH, Nomura M, et al. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS One. 2019;14(5):e0216954. doi:https://doi.org/10.1371/journal.pone.0216954.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Iwama S, Yasuda Y, Okada N, Okuji T, Ito M, et al. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer. 2020;8(2):e000779. doi:https://doi.org/10.1136/jitc-2020-000779.
   PubMed Web of Science ®Google Scholar
• Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, et al. Prognostic impact and risk factors of immune-related pneumonitis in patients with non-small-cell lung cancer who received programmed death 1 inhibitors. Clin Lung Cancer. 2019;20(6):442–450.e4. doi:https://doi.org/10.1016/j.cllc.2019.07.006.
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Aithal GP, Björnsson ES, Kaplowitz N, Kullak-Ublick GA, Larrey D, Karlsen TH. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019;70(6):1222–1261. doi:https://doi.org/10.1016/j.jhep.2019.02.014.
   PubMed Web of Science ®Google Scholar
• Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806–15. doi:https://doi.org/10.1038/clpt.2011.58.21544079
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, National Comprehensive Cancer Network, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–1768. doi:https://doi.org/10.1200/JCO.2017.77.6385.
   PubMed Web of Science ®Google Scholar
• Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K, ESMO Guidelines CommitteeManagement of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119–42. doi:https://doi.org/10.1093/annonc/mdx225.
   PubMed Web of Science ®Google Scholar
• Peeraphatdit T, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology. 2020;72(1):315–329. doi:https://doi.org/10.1002/hep.31227.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software “'EZR' for medical statistics”. Bone Marrow Transplant. 2013;48(3):452–458. doi:https://doi.org/10.1038/bmt.2012.244.
   PubMed Web of Science ®Google Scholar
• Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, et al. Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer. JAMA Oncol. 2020;6(12):1952–1956.
   PubMed Web of Science ®Google Scholar
• Yokohama K, Asai A, Matsui M, Okamoto N, Yasuoka H, Nishikawa T, et al. Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy. Sci Rep. 2020;10(1):14470. doi:https://doi.org/10.1038/s41598-020-71561-2.
   Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. doi:https://doi.org/10.1056/NEJMoa1504627.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi:https://doi.org/10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar